Dienedione

Synopsis

Dienedione (Estra-4,9-diene-3,17-dione): A Comprehensive Reference

Identity and Chemical Characterization

Names and Identifiers

Dienedione, also known as estra-4,9-diene-3,17-dione, is a synthetic, orally active anabolic-androgenic steroid (AAS) of the 19-nortestosterone group that was never introduced for medical use. Its systematic IUPAC name is estra-4,9-diene-3,17-dione, and it is also referred to in chemical and regulatory literature as 19-nor-4,9(10)-androstadienedione or 19-norandrosta-4,9-diene-3,17-dione. It is known by synonyms such as Dienedione and 19-Norandrosta-4,9-diene-3,17-dione, and is a synthetic, orally active anabolic-androgenic steroid (AAS). The compound is assigned CAS Registry Number 5173-46-6.

With a molecular formula of C₁₈H₂₂O₂ and a molecular weight of 270.37 g/mol, it is supplied as a white to off-white powder with a melting point of approximately 138–144 °C. Dienedione belongs to the estrane (18-carbon) steroid scaffold, distinguishable from classical androgens by the absence of the C-19 methyl group — the defining feature of the 19-nortestosterone family. Its two conjugated ketone groups are located at the C-3 and C-17 positions, and the two double bonds are positioned at C-4 and C-9(10), creating a highly conjugated diene system. It is thought to be a prohormone of dienolone.

Related Compounds

Dienedione (the 17-keto analogue of dienolone, also known as 19-nor-4,9-androstadienedione) is thought to be a prohormone of dienolone, while methyldienolone and ethyldienolone are orally active 17α-alkylated AAS derivatives of dienolone. In contrast, dienogest, the 17α-cyanomethyl derivative of dienolone, is a potent progestogen and antiandrogen. Structurally, dienedione is a diene analogue of bolandione (19-nor-androstenedione), and a 9,10-dehydro analogue of nandrolone's immediate ketone precursor. The related veterinary and illicit performance-enhancement compound trenbolone also shares the 19-nor-4,9-diene core, and dienedione finds use as a synthetic stepping stone toward trenbolone. Whilst dienedione can be used as a precursor to trenbolone, it is also fully possible to employ dienolone (dehydronandrolone), as was recently claimed.

Physical Properties and Solubility

Dienedione is a crystalline solid under ambient conditions. Its high degree of lipophilicity, conferred by the steroidal tetracyclic carbon skeleton, renders it insoluble in water but soluble in common organic solvents. As a research chemical and pharmaceutical intermediate, it is commercially produced in high-purity form. Purified estra-4,9-diene-3,17-dione serves as a reference standard for the development and validation of analytical methods in forensic and sports science laboratories.

Natural Sources and Occurrence

Dienedione is a wholly synthetic compound and has no botanical origin. While not a traditional herbal remedy, dienedione's introduction into nutritional regimens reflects a modern approach to optimizing human performance. The compound does not occur naturally in plants, fungi, or microorganisms, and there is no traditional or ethnobotanical history of its use.

An important qualification emerged from recent doping-control research: with the rare presence of the 4,9-diene configuration in endogenous steroids, dienedione has been considered as a synthetic AAS; nevertheless, the reoccurring detection of dienedione in entire male horse urine samples led to the investigation of its possible endogenous nature in horses, and its endogenous nature in entire male horses has been recently confirmed. Qualitative analyses showed that dienedione was endogenous in colt urine and mainly in the form of glucuronide conjugates. While dienedione is not detected in castrated horses (geldings), it is essential to study its elimination and identify its metabolites for its effective control. This finding in equines does not establish natural occurrence in humans; with no report of 4,9-diene configuration in endogenous steroids, dienedione has long been considered a synthetic AAS in humans.

Historical and Commercial Background

Origins and Development

Historically identified as an orally active anabolic-androgenic steroid (AAS) from the 19-nortestosterone group, it was initially developed as a prohormone to the active metabolite dienolone. Dienedione gained popularity in the early 2000s among athletes and fitness enthusiasts seeking performance enhancement and muscle growth. It was not developed through formal pharmaceutical research pipelines nor subjected to Phase I–III clinical trials prior to its appearance on the supplement market.

Dienolone fits the profile as a potent 19-nortestosterone derivative never approved for therapeutic purposes, with its unsaturation at the 4,9(10)-positions enhancing anabolic potency relative to nandrolone while reducing detectability in standard doping tests. The substance gained notoriety in underground fitness circles during the early 2000s as a "trenbolone analog," sold under proprietary blends like Trenazone for its purported rapid muscle-building and strength-enhancing effects without the side effects of traditional injectables.

The drug became a controlled substance in the US on January 4, 2010, and is classified as a Schedule III anabolic steroid under the United States Controlled Substances Act. Previous to this, it was sold as a bodybuilding supplement within the United States.

Supplement Market Context

Estra-4,9-diene-3,17-dione (dienedione) is an anabolic-androgenic steroid (AAS) available on the market as a dietary supplement for bodybuilding. It circulated primarily as an oral capsule or tablet, often sold alone or in multi-ingredient "prohormone stacks." Since the majority of these compounds are available only on the Internet, their biological activity and the extent of their use is difficult to determine. 'Designer' steroids are problematic since it is difficult to obtain ethical approval for in vivo metabolism studies due to a lack of a toxicological profile.

Traditional Use

Dienedione has no traditional use in any formal sense. It is a fully synthetic steroid created in the late twentieth century, with no history in Ayurvedic, Traditional Chinese Medicine, Native American, European, or any other ethnobotanical or traditional healing system. Originally developed and popularized in the early 2000s, dienedione was marketed as a prohormone, intended to support muscle growth, enhance physical strength, and improve overall vitality. Its use was confined entirely to the modern bodybuilding and sports-performance supplement market, representing a category of compounds often referred to as "designer steroids" — synthetic molecules engineered to mimic or surpass classical anabolic steroids while temporarily evading regulatory frameworks.

Chemical Synthesis and Pharmaceutical Significance

Synthetic Routes

Several synthetic routes to dienedione have been described in the patent and primary literature. One semi-synthetic approach proceeds from estrone methyl ether through Birch reduction and subsequent chemical transformations. This is produced from estrone 3-methyl ether by protection as the ketal, Birch reduction of the aromatic group, and acid hydrolysis. The procedure involved ketalization of both carbonyl groups with concomitant olefin migration from C4 to C5(10), epoxide formation with m-CPBA, hydrolysis of the oxirane, and dehydration in concentrated acid solution.

A fully semi-synthetic Organon route has also been reported. The first step consists of a Grignard reaction with 5-chloro-2-pentanone-neopentylacetal to give an intermediate octahydroindene compound. Halogenation with chlorine gas in the presence of pyridine base gives a further seco-ester intermediate. The hydrolysis of the ketal in weak acid leads to the trione intermediate. Lastly, an intramolecular aldol condensation in the presence of t-BuOK base completes the synthesis of dienedione.

A simplified Chinese patent route has been described: the method comprises contacting 19-hydroxy-4-androstenedione with lead tetraacetate in an organic solvent, conducting degradation esterification on 19-hydroxy, and collecting the corresponding product; the product is then reacted with p-toluenesulfonic acid to yield the target estra-4,9-diene-3,17-dione. The preparation method has the advantages of a short synthetic route, high yield, and small environmental pollution.

Role as a Pharmaceutical Intermediate

This product is recognized for its role as a key advanced intermediate in the synthesis of various pharmaceutical compounds, most notably mifepristone. Mifepristone (RU-486) is a well-characterized antiprogestogen and antiglucocorticoid used in approved medical protocols; the 4,9-diene steroidal framework of dienedione is elaborated in multiple steps to furnish the C-11 aryl and C-17 propynyl substituents of mifepristone. Estra-4,9-diene-3,17-dione occupies a unique position, being both a legitimate chemical intermediate and a controlled substance.

Key Constituents and Active Compounds

Dienedione is itself a single, well-defined chemical entity with the molecular formula C₁₈H₂₂O₂. Unlike botanical preparations, it does not contain a mixture of phytochemicals. Its biological activity derives from both its intrinsic properties and its conversion to the active metabolite dienolone in vivo.

Mechanisms of Action

Prohormone Conversion to Dienolone

Dienedione serves as the 17-keto prohormone of dienolone, which is converted to the active dienolone via enzymatic reduction by 17β-hydroxysteroid dehydrogenase (17β-HSD) in vivo. This reduction at the C-17 carbonyl introduces a 17β-hydroxyl group, yielding dienolone — the pharmacologically active species. This mechanism is analogous to the established conversion of androstenedione to testosterone, and of bolandione to nandrolone, both catalyzed by 17β-HSD isoforms. This includes interconversion of DHEA and androstenediol, androstenedione and testosterone, and estrone and estradiol. The major reactions catalyzed by 17β-HSD (such as the conversion of androstenedione to testosterone) are hydrogenation (reduction) reactions, rather than dehydrogenation.

Androgen Receptor Activity of the Metabolite Dienolone

The active metabolite dienolone has been characterized in preclinical receptor-binding assays. It has been found to possess slightly lower affinity for the androgen receptor (AR) and progesterone receptor (PR) relative to nandrolone in rat and rabbit tissue bioassays, whereas trenbolone was found to possess the same affinity for the AR as dienolone but several-fold increased affinity for the PR. These data indicate that the anabolic and androgenic effects of dienolone — and therefore of dienedione as its prohormone — are mediated primarily through androgen receptor binding, with concomitant progesterone receptor activity.

Early pharmacological studies indicate that dienolone possesses myotrophic and nitrogen-retaining effects characteristic of anabolic-androgenic steroids (AAS), with structure-activity relationships suggesting a favorable anabolic profile relative to its analogs. It lacks significant estrogenic activity, as it does not undergo aromatization to estrogens.

Endocrine Axis Effects

Like all exogenous anabolic steroids and their prohormones, administration of dienedione would be expected to suppress the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback. Research on closely related "designer" prohormone compounds has documented measurable endocrine perturbations. Metandienone and estradienedione, but not S-1, administration significantly decreases LH and inhibin B serum concentrations. Administration of estradienedione resulted in an increase of E2.

At supraphysiological doses, androgens and their prohormones exert additional endocrine effects. Supraphysiological doses can displace the cortisol from its receptors, inhibiting its catalytic effects. In the thyroids, which have androgen receptors, they can alter function, with a decrease in total thyroxine and triiodothyronine and in the transporter globulin. In addition, gonadal steroids are the biggest regulator of the somatotropic axis, stimulating growth hormone secretion and the formation of IGF-1.

In Vitro Metabolism Research

Effective detection of the abuse of androgenic-anabolic steroids in human and animal sports often requires knowledge of the drug's metabolism in order to target appropriate urinary metabolites. Designer steroids are problematic since it is difficult to obtain ethical approval for in vivo metabolism studies due to a lack of a toxicological profile. In this study (Scarth et al., 2010), the in vitro metabolism of estra-4,9-diene-3,17-dione is reported for the first time. This is also the first study comparing the metabolism of a designer steroid in the three major species subject to sports doping control; namely the equine, canine and human.

The major metabolite detected in all species, and therefore the most suitable candidate for screening of estra-4,9-diene-3,17-dione abuse, was proposed to be an isomer of 17-hydroxy-estra-4,9-dien-3-one. Less significant metabolic pathways in all species included hydroxylation and reduction followed by hydroxylation. Reductive metabolism in the canine was less significant than in the other two species, while the equine was unique in producing a di-reduced metabolite (proposed to be an isomer of estra-4,9-diene-3,17-diol) and also relatively large quantities of D-ring hydroxy and hydroxy-reduced metabolites.

In equine doping-control experiments, to control the misuse of dienedione in geldings, M3a and M3b are the potential target metabolites that gave the longest detection time, which could be detected for up to 2–5 days in urine and 0.4–4 days in plasma.

Scientific Evidence by Area of Use

Muscle Anabolism and Body Composition

Evidence quality: Absent (no controlled human clinical trials identified).

While anecdotal reports suggest that dienedione may contribute to increased lean muscle mass and improved recovery times, robust clinical evidence supporting its efficacy is limited. Most of the scientific understanding of dienedione's effects is derived from its structural similarity to other anabolic steroids, which have been more extensively studied. These compounds are known to promote protein synthesis and nitrogen retention, theoretically leading to enhanced muscle development.

No prospective randomized controlled trials of dienedione in human subjects were identified in the peer-reviewed literature. The compound became a Schedule III controlled substance in the United States in 2010, which effectively prohibits human clinical research without DEA authorization. Any mechanistic inferences regarding muscle anabolism in humans are therefore extrapolated from: (1) the receptor pharmacology of its active metabolite dienolone in animal-tissue bioassays, and (2) the known biology of structurally related 19-nortestosterone derivatives such as nandrolone.

Athletic Performance Enhancement

Evidence quality: Absent (no controlled human studies).

Dienedione is prohibited in both human and equine sports due to its potential performance-enhancing effect. However, prohibition by anti-doping bodies is based on pharmacological class and structural similarity to known anabolic agents, not on the results of prospective performance trials in athletes. No published clinical trials assessing exercise performance, strength, or power output following dienedione supplementation were identified. The compound's classification as an anabolic agent by WADA and its Schedule III status in the US have rendered controlled human research effectively impossible since 2010.

Endocrine Effects (Hormonal Changes)

Evidence quality: In vitro / preclinical; limited human observational data from related compounds.

The endocrine effects of dienedione are documented indirectly through its metabolite's receptor pharmacology. As noted, dienolone has been found to possess slightly lower affinity for the androgen receptor (AR) and progesterone receptor (PR) relative to nandrolone in rat and rabbit tissue bioassays, whereas trenbolone was found to possess the same affinity for the AR as dienolone but several-fold increased affinity for the PR. One study specifically examining a closely related compound found that estradienedione administration significantly decreases LH and inhibin B serum concentrations, and resulted in an increase in E2. The suppression of LH and inhibin B is consistent with the expected negative feedback of exogenous androgens on the hypothalamic-pituitary axis.

Doping Detection and Forensic Pharmacology

Evidence quality: Peer-reviewed, well-characterized (in vitro and in vivo animal studies).

The most substantial peer-reviewed scientific literature on dienedione concerns its metabolism in the context of doping control. Comparative in vitro metabolism of the designer steroid estra-4,9-diene-3,17-dione between the equine, canine and human has been studied to identify target metabolites for use in sports doping control. This research characterized the metabolic pathways and proposed appropriate urinary detection targets.

In a subsequent in vivo equine study, while dienedione is not detected in castrated horses (geldings), it was essential to study its elimination and identify its metabolites for effective control. Administration experiments were performed by giving three castrated horses (geldings) each a single oral dose of 1500 mg of dienedione.

Qualitative and quantitative analyses of dienedione content in colt urine were performed employing liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Qualitative analyses showed that dienedione was endogenous in colt urine and mainly in the form of glucuronide conjugates. A possible in-house threshold was proposed at 30 ng/mL of free and glucuronide-conjugated dienedione in colt urine, associated with a risk factor of 1 in 14,269 (with a degree of freedom of 173). This is the first report of endogenous dienedione in entire male horses, and the approach for controlling its potential misuse by using a threshold is also presented.

Body Systems and Health Areas Associated with Dienedione

Musculoskeletal System

The compound is categorized as an anabolic-androgenic steroid, and its metabolite dienolone has been shown preclinically to possess myotrophic and nitrogen-retaining properties. Early pharmacological studies indicate that dienolone possesses myotrophic and nitrogen-retaining effects characteristic of anabolic-androgenic steroids (AAS), with structure-activity relationships suggesting a favorable anabolic profile relative to its analogs. These are properties associated in the wider AAS class with skeletal muscle hypertrophy.

Endocrine System

Dienedione directly engages the hormonal axes of the endocrine system, both through its own activity and through conversion to dienolone. Exogenous AAS and their prohormones are well-documented to suppress hypothalamic-pituitary-gonadal axis function via negative feedback, reduce endogenous testosterone production, and alter the balance of gonadotropins. Supraphysiological doses can displace cortisol from its receptors, inhibiting its catalytic effects.

Hepatic System

Dienedione is metabolized in the liver, the primary site of steroid biotransformation. Hepatotoxicity is a class-related concern for anabolic-androgenic steroids. Various hepatic abnormalities have been described in the AAS class, ranging from mild, temporary increases in transaminases to severe, permanent forms, depending on the doses, time of administration, and most of all the type; alkylated compounds are particularly hepatotoxic, although it can occur with any androgen. Hyperplasia and cholestasis can occur with an elevation in bilirubin, alkaline phosphatase, and LDH with dose-dependent jaundice, and can yield upon stopping use. Dienedione itself does not carry a 17α-alkyl group (which is the primary driver of the most severe hepatotoxicity in the AAS class), but liver involvement through first-pass metabolism remains pharmacologically relevant.

Cardiovascular System

Anabolic-androgenic steroid use as a class is associated with adverse cardiovascular effects including dyslipidemia, left ventricular hypertrophy, and increased risk of thromboembolic events. No specific, dienedione-specific cardiovascular data from controlled human studies were identified in the peer-reviewed literature.

Reproductive System

Via suppression of LH and inhibin B — both demonstrated for closely related estradienedione compounds in the cited research — dienedione is implicated in suppression of gonadal function. Estradienedione administration significantly decreases LH and inhibin B serum concentrations and resulted in an increase of E2. The progesterone receptor activity of the active metabolite dienolone also implies potential reproductive endocrine effects beyond androgenic suppression alone.

Dosage Forms and Reported Dosages

Prior to its scheduling as a controlled substance, dienedione was commercially available primarily as an oral capsule or tablet intended for dietary supplement use. Specific dosage regimens in human subjects have not been established through formal clinical trials.

The only peer-reviewed dosage data published concerns the equine administration study conducted for doping-control purposes: while dienedione is not detected in castrated horses (geldings), to study the elimination and biotransformation of dienedione, administration experiments were performed by giving three castrated horses (geldings) each a single oral dose of 1500 mg of dienedione. This dose was chosen to enable detection and metabolite characterization for anti-doping purposes and does not represent a therapeutic or supplemental dosage for humans.

No peer-reviewed human clinical dosage data were identified. Because the compound became a Schedule III controlled substance in the United States as of January 4, 2010, and because the UK Advisory Council on the Misuse of Drugs (ACMD) recommended its classification as a Class C substance, formal human dosing studies would require controlled-substance research authorization and have not been published.

Regulatory Status

United States

The drug became a controlled substance in the US on January 4, 2010, and is classified as a Schedule III anabolic steroid under the United States Controlled Substances Act. The compound is explicitly listed under Schedule III as 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione). Possession, distribution, or manufacture without DEA authorization is a federal crime under 21 U.S.C.

United Kingdom

Les Iversen, chair of the ACMD, wrote to the Minister for Preventing Abuse and Exploitation, recommending that estra-4,9-diene-3,17-dione be made a Class C controlled substance. The ACMD therefore recommended that estra-4,9-diene-3,17-dione be controlled under the Misuse of Drugs Act 1971 in Class C and as a Schedule 4 (IV) Part 2 substance under the Misuse of Drugs Regulations 2001.

Canada

A 2011 decision by Health Canada listed dienolone (the active metabolite) as a controlled substance under anabolic steroid regulations, specifically under Item 23 of Schedule IV to the Controlled Drugs and Substances Act, capturing it as a derivative and metabolite of related designer steroids.

International Anti-Doping

Its status as a synthetic AAS led to its prohibition in human and equine sports by the World Anti-Doping Agency (WADA) and the Fédération Équestre Internationale (FEI). Internationally, dienolone (and by extension its prohormone dienedione) has been banned by the World Anti-Doping Agency (WADA) since 2005 as an anabolic agent in the prohibited list, applicable in and out of competition for athletes. It has no Anatomical Therapeutic Chemical (ATC) classification code, as it was never approved for therapeutic use by any regulatory authority.

Safety Considerations

Absence of Formal Toxicological Profile

Designer steroids are problematic since it is difficult to obtain ethical approval for in vivo metabolism studies due to a lack of a toxicological profile. No formal preclinical toxicology package (GLP animal studies, reproductive toxicology, carcinogenicity studies) has been published for dienedione. Its rapid scheduling in the US and UK was based on pharmacological class characterization rather than on the results of completed safety studies.

Endocrine Suppression

The evidence from studies of closely related estradienedione compounds documents that administration significantly decreases LH and inhibin B serum concentrations and results in an increase of E2, indicating suppression of the hypothalamic-pituitary-gonadal axis and potential estrogenic elevation from aromatizable metabolites. This pattern is consistent with the known endocrine effects of AAS class compounds and their prohormones.

Hepatic Considerations

Various hepatic abnormalities have been described in the AAS class, ranging from mild, temporary increases in transaminases to severe, permanent forms depending on the doses, time of administration, and most of all the type. While dienedione is not 17α-alkylated (the structural feature associated with the most acute oral hepatotoxicity), metabolism through the liver is unavoidable for an orally administered steroid. Hepatic impact specific to dienedione has not been characterized in controlled human studies.

Cardiovascular Risk Profile

By class extrapolation from anabolic-androgenic steroid pharmacology, gonadal steroids are the biggest regulator of the somatotropic axis, stimulating growth hormone secretion and the formation of IGF-1. Disruption of the endocrine axis by AAS-class compounds is associated with adverse lipid profiles (suppression of HDL, elevation of LDL) and cardiovascular remodeling, although no specific dienedione cardiovascular data are available.

Detection and Legal Risk for Athletes

The status of dienedione as a synthetic AAS led to its prohibition in human and equine sports by WADA and the FEI. Metabolites of dienedione can be detected for up to 2–5 days in urine and 0.4–4 days in plasma in equine models; the detection window in human urine was characterized in the foundational Scarth et al. (2010) in vitro study, which identified an isomer of 17-hydroxy-estra-4,9-dien-3-one as the major urinary metabolite and recommended it as the primary doping-control target. An anti-doping rule violation arising from a positive test for dienedione or its metabolites constitutes a serious doping offense under the WADA Code.

Absence of Approved Medical Use

Dienedione is a synthetic, orally active anabolic-androgenic steroid (AAS) that was never introduced for medical use. It has no Anatomical Therapeutic Chemical (ATC) classification code, as it was never approved for therapeutic use by any regulatory authority. There is no evidence base to support its use for any diagnosed medical condition.

Research Gaps and Limitations of Existing Evidence

The evidence base for dienedione is severely constrained by several factors:

No human clinical trials: Robust clinical evidence supporting its efficacy is limited. No prospective, randomized, placebo-controlled studies of its effects in humans have been published.
No formal toxicology: Designer steroids are problematic since it is difficult to obtain ethical approval for in vivo metabolism studies due to a lack of a toxicological profile.
Indirect receptor data only: Most of the scientific understanding of dienedione's effects is derived from its structural similarity to other anabolic steroids, which have been more extensively studied.
Regulatory barriers: Classification as a Schedule III controlled substance in the US since 2010 and as a Class C drug in the UK prevents mainstream clinical investigation.
Publication bias: Nearly all published science on dienedione concerns its detection and metabolism for doping-control purposes, not its safety or therapeutic potential.
Animal data limitations: The confirmed endogenous status of dienedione in entire male horses, while scientifically important for equine doping control, does not translate directly to conclusions about the compound's safety or activity in humans.